Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Detection
Event summary
- Labcorp will offer the Elecsys® pTau-217 blood test, the first FDA-cleared single-biomarker test to detect Alzheimer's disease pathology.
- The test is designed for individuals 55 and older with signs of cognitive decline and can be used in both primary and specialty care settings.
- Labcorp plans to make the test available nationwide in the coming months.
- The test measures phosphorylated Tau 217 (pTau-217), a key indicator of amyloid pathology associated with Alzheimer's disease.
The big picture
Labcorp's launch of the Elecsys® pTau-217 test aligns with the growing trend of blood-based diagnostics in neurology, offering a less invasive alternative to cerebrospinal fluid (CSF) testing and positron emission tomography (PET) imaging. The test's standardization across care settings could streamline Alzheimer's disease evaluation, potentially reducing the burden on patients and clinicians. With an aging population and increasing demand for early detection, this development positions Labcorp as a key player in the diagnostic segment of neurodegenerative disease management.
What we're watching
- Market Adoption
- The pace at which primary care physicians adopt the test will determine its impact on early Alzheimer's detection.
- Competitive Dynamics
- Whether Labcorp can maintain a competitive edge with its standardized approach amid other pTau-217 assays.
- Regulatory Compliance
- How the FDA's oversight of blood-based biomarkers evolves as more tests enter the market.
Related topics